Sarepta Therapeutics, Inc. (SRPT) is a Biotechnology company in the Healthcare sector, currently trading at $22.15. It has a SharesGrow Score of 49/100, indicating a mixed investment profile with 1 out of 7 criteria passed.
Analyst consensus target is SRPT = $25 (+10.6% upside).
Valuation: SRPT trades at a trailing Price-to-Earnings (P/E) of -3.2 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.06.
Financials: revenue is $2.2B, +33.9%/yr average growth. Net income is $713M (loss), growing at -78.5%/yr. Net profit margin is -32.5% (negative). Gross margin is 59.9% (-25.1 pp trend).
Balance sheet: total debt is $1.0B against $1.1B equity (Debt-to-Equity (D/E) ratio 0.91, moderate). Current ratio is 2.32 (strong liquidity). Debt-to-assets is 31%. Total assets: $3.3B.
Analyst outlook: 30 / 54 analysts rate SRPT as buy (56%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 88/100 (Pass), Growth 58/100 (Partial), Past 25/100 (Fail), Health 50/100 (Partial), Moat 59/100 (Partial), Future 52/100 (Partial), Income 10/100 (Fail).
